Keywords: NXL stock, Nexalin Technology, 1-for-30 reverse split, Nasdaq compliance, neurostimulation stocks, medical device micro-cap, DIFS, stockholders equity requirement, premarket movers

What Happened

Nexalin Technology, Inc. declined about 21% on Tuesday to close at $2.64, continuing a longer downtrend for the medical-device micro-cap focused on neurostimulation products. Pre-market today the stock was roughly flat to slightly lower near $2.61. The stock remains under pressure from ongoing losses, low revenue and general micro-cap selling.

The Reverse Split and What Followed

The board approved a 1-for-30 reverse stock split to protect compliance with Nasdaq's bid-price rule. It took effect on August 28, with split-adjusted trading starting August 31 under the same NXL ticker. Before the split, the stock closed near $0.29, which equals about $8.70 on a split-adjusted basis. A $2.64 close is therefore roughly 70% lower in about six weeks.

The split did its job on paper. On September 30, Nasdaq confirmed that the closing bid stayed above $1.00 for 21 consecutive trading days, from August 31 through September 29, restoring bid-price compliance. That followed a September 25 decision by the Nasdaq Hearings Panel granting continued listing. A reverse split lifts the share price, but it does not change the underlying economics of the business.

The Next Hurdle

Under the Panel's terms, Nexalin must show a minimum of $2.5 million in stockholders' equity by January 4, 2027. The company has warned there is no assurance it can do so or maintain compliance with Nasdaq's other requirements. With ongoing losses and low revenue, equity is the pressure point, and meeting it may require raising capital, which could dilute shareholders.

Management has pursued distribution agreements, including in South America, and clinical advancement. Fundamentals, however, remain challenged, and the share price reflects that. For shareholders, the sequence matters. Companies that complete a reverse split often see the post-split price slide as the lower share count meets continued selling, and Nexalin's chart fits that pattern. Whether the stock stabilizes depends on whether it can lift revenue, control losses and strengthen its balance sheet before the January deadline arrives. Any new equity raise could add further pressure on the price.

Key Highlights

  • Shares fall 21% to $2.64: The downtrend continues, with pre-market near $2.61.
  • 1-for-30 reverse split: Effective August 28, with split-adjusted trading from August 31.
  • Bid-price compliance regained: Nasdaq confirmed 21 straight trading days above $1.00, from August 31 to September 29.
  • Equity deadline: Nexalin must show $2.5 million in stockholders' equity by January 4, 2027.
  • About 70% lower since the split: The close compares with a split-adjusted pre-split level near $8.70.

Company Overview

Nexalin Technology, Inc. is a Houston-based medical device company developing non-invasive neurostimulation products. Its technology, Deep Intracranial Frequency Stimulation (DIFS), applies electrical stimulation through the head to reach deep regions of the brain, with a focus on mental health disorders. The company earns money by selling its devices through clinics and distributors, and it has pursued distribution agreements in markets such as South America. It also spends on clinical work to support its devices. Revenue is low and losses continue, so the business relies on capital raising to fund growth.

Disclaimer: This content is for information only and is not financial advice or a recommendation to buy or sell any security. Micro-cap and small-cap stocks carry high risk, including loss of capital. Prices reflect the data supplied and may change. Please do your own research or consult a licensed adviser.